Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 11/20 | 0.40 |
| ▸ | DRD4 | P21917 | 9/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4212232 | 0.85 | MCHR1 (0.49) | HPGDDRD2DRD4 | |
| SCHEMBL4212228 | 0.85 | MCHR1 (0.49) | HPGDDRD2DRD4 | |
| SCHEMBL4217091 | 0.84 | DRD2 (0.40) | DRD2DRD4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4207301 | 0.84 | DRD2 (0.39) | DRD2DRD4CCR1SLC6A2SLC6A4 | |
| SCHEMBL13928754 | 0.81 | SMN1; SMN2 (0.52) | HPGDDRD2DRD4 | |
| SCHEMBL13928763 | 0.81 | HPGD (0.46) | HPGDDRD2DRD4CCR1SLC6A2 | |
| SCHEMBL4218054 | 0.80 | MCHR1 (0.52) | HPGD | |
| SCHEMBL4208589 | 0.80 | HPGD (0.45) | HPGDDRD2DRD4CCR1SLC6A2 | |
| SCHEMBL13928766 | 0.77 | HPGD (0.43) | HPGD | |
| SCHEMBL4204597 | 0.77 | HPGD (0.42) | HPGDDRD2DRD4CCR1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488738-B2 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | ASUBIO PHARMA CO., LTD. (JP) | 2009-02-10 | — | — | US | disclosed |
| US-7488738-B2 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | ASUBIO PHARMA CO., LTD. (JP) | 2009-02-10 | — | — | US | disclosed |
| US-7488738-B2 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | ASUBIO PHARMA CO., LTD. (JP) | 2009-02-10 | — | — | US | disclosed |
| US-6998401-B2 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | SUNTORY LIMITED (JP) | 2006-02-14 | — | — | US | disclosed |
| US-20050245574-A1 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1045693-B1 | AMINOPHENOXYACETIC ACID DERIVATIVES AS NEUROPROTECTANTS | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2004-06-30 | — | — | EP | disclosed |
| US-20040063748-A1 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | ASUBIO PHARMA CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245574-A1 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | CAMK2A, CAMK2B, SLC1A2 | HPGD 3258/4885DRD2 679/4885DRD4 1044/4885 |
| US-20040063748-A1 | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof | FABP7, SLC1A2, CAMK2A | HPGD 3594/4885DRD2 565/4885DRD4 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.